Two biopharmas, Alexion Pharmaceuticals and Karyopharm, are trialing possible treatments while Eli Lilly and Bristol Myers Squibb are offering to help the unemployed stay on their meds.
Meanwhile, President Donald Trump offered U.K. Prime MInister Boris Johnson, in the ICU with COVID-19, unproven treatments. And news emerged that Trump himself holds a small financial interest in Sanofi, which makes an off-patent brand of hydroxychloroquine.
India is reportedly retracting export bans on 13 active pharmaceutical ingredients and finished formulations, and hydroxychloroquine may be included.
As of Tuesday, the number of global confirmed cases had surpassed 1.36 million, according to Johns Hopkins University’s real-time dashboard, and nearly 76,000 people had died.
See all of FiercePharma’s COVID-19 coverage here
By Eric Sagonowsky, Kyle Blankenship, Angus Liu, Conor Hale
Source: Fierce Pharma
The appointment makes Tuyen Ong the latest in a series of new CEO-partners hired by Flagship. Flagship Pioneering has named Tuyen Ong as CEO-partner. The new role sees the ex-Biogen […]
The COVID-19 pandemic has millennials worried—and that has them planning to buy more prescription drugs in the future, new research finds. WPP’s global media group, Mindshare, began surveying consumers in […]
AstraZeneca has received an investment of approximately $486m from the US Government to develop and supply its long-acting antibody (LAAB) cocktail, AZD7442, for Covid-19 treatment. AstraZeneca has received an investment […]